The invention provides a method of treating a mammal having, or at risk
of, an indication associated with a TGF-beta deficiency comprising
administering one or more agents that is effective to elevate the level
of TGF-beta. The invention also provides novel compounds that elevate
TGF-beta levels, as well as pharmaceutical compositions comprising
compounds that elevate TGF-beta levels, and methods for detecting
diseases associated with endothelial cell activation.